Ionis Total Current Assets vs Total Stockholder Equity Analysis

IONS Stock  USD 37.31  0.31  0.82%   
Ionis Pharmaceuticals financial indicator trend analysis is infinitely more than just investigating Ionis Pharmaceuticals recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Ionis Pharmaceuticals is a good investment. Please check the relationship between Ionis Pharmaceuticals Total Current Assets and its Total Stockholder Equity accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Ionis Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors.
For more information on how to buy Ionis Stock please use our How to Invest in Ionis Pharmaceuticals guide.

Total Current Assets vs Total Stockholder Equity

Total Current Assets vs Total Stockholder Equity Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Ionis Pharmaceuticals Total Current Assets account and Total Stockholder Equity. At this time, the significance of the direction appears to have strong relationship.
The correlation between Ionis Pharmaceuticals' Total Current Assets and Total Stockholder Equity is 0.7. Overlapping area represents the amount of variation of Total Current Assets that can explain the historical movement of Total Stockholder Equity in the same time period over historical financial statements of Ionis Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Ionis Pharmaceuticals' Total Current Assets and Total Stockholder Equity is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Current Assets of Ionis Pharmaceuticals are associated (or correlated) with its Total Stockholder Equity. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Stockholder Equity has no effect on the direction of Total Current Assets i.e., Ionis Pharmaceuticals' Total Current Assets and Total Stockholder Equity go up and down completely randomly.

Correlation Coefficient

0.7
Relationship DirectionPositive 
Relationship StrengthSignificant

Total Current Assets

The total value of all assets that are expected to be converted into cash within one year or during the normal operating cycle.

Total Stockholder Equity

The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.
Most indicators from Ionis Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Ionis Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Ionis Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors.
For more information on how to buy Ionis Stock please use our How to Invest in Ionis Pharmaceuticals guide.At this time, Ionis Pharmaceuticals' Selling General Administrative is comparatively stable compared to the past year. Tax Provision is likely to gain to about 33.9 M in 2024, whereas Sales General And Administrative To Revenue is likely to drop 0.16 in 2024.
 2021 2022 2023 2024 (projected)
Total Operating Expenses829M984M1.1B1.2B
Cost Of Revenue11M14M9.1M8.7M

Ionis Pharmaceuticals fundamental ratios Correlations

0.850.580.920.730.86-0.16-0.60.680.940.61.00.590.930.950.940.931.00.30.740.520.50.830.960.430.64
0.850.730.920.30.950.25-0.80.380.670.140.850.460.970.920.810.970.870.220.70.50.610.970.830.370.29
0.580.730.650.110.650.36-0.530.110.540.190.580.220.690.570.50.690.58-0.460.420.410.350.710.560.230.21
0.920.920.650.430.930.18-0.80.40.790.330.910.50.970.920.890.980.930.340.720.670.610.910.910.430.33
0.730.30.110.430.38-0.75-0.040.90.830.870.730.590.430.60.670.430.70.240.50.180.090.260.670.320.86
0.860.950.650.930.380.17-0.840.430.720.180.860.570.940.920.880.940.880.320.810.50.490.940.850.520.25
-0.160.250.360.18-0.750.17-0.38-0.8-0.31-0.62-0.17-0.40.17-0.06-0.180.17-0.14-0.09-0.110.090.30.33-0.1-0.13-0.64
-0.6-0.8-0.53-0.8-0.04-0.84-0.38-0.12-0.420.12-0.6-0.62-0.78-0.64-0.76-0.78-0.62-0.27-0.8-0.7-0.47-0.81-0.54-0.710.07
0.680.380.110.40.90.43-0.8-0.120.720.690.690.660.440.630.670.430.670.230.530.230.090.280.610.350.79
0.940.670.540.790.830.72-0.31-0.420.720.810.930.570.780.820.870.780.920.160.660.480.310.640.910.420.72
0.60.140.190.330.870.18-0.620.120.690.810.590.360.30.390.480.30.56-0.030.260.250.020.10.570.160.83
1.00.850.580.910.730.86-0.17-0.60.690.930.590.60.930.950.940.931.00.30.740.520.490.830.950.430.65
0.590.460.220.50.590.57-0.4-0.620.660.570.360.60.490.520.780.490.590.20.880.530.130.420.460.860.38
0.930.970.690.970.430.940.17-0.780.440.780.30.930.490.940.881.00.940.280.730.560.610.960.890.390.4
0.950.920.570.920.60.92-0.06-0.640.630.820.390.950.520.940.890.940.960.380.730.420.540.890.950.330.5
0.940.810.50.890.670.88-0.18-0.760.670.870.480.940.780.880.890.880.940.350.880.640.440.790.860.70.51
0.930.970.690.980.430.940.17-0.780.430.780.30.930.491.00.940.880.940.290.730.580.610.960.90.40.39
1.00.870.580.930.70.88-0.14-0.620.670.920.561.00.590.940.960.940.940.320.750.520.530.850.950.420.62
0.30.22-0.460.340.240.32-0.09-0.270.230.16-0.030.30.20.280.380.350.290.320.290.10.330.240.330.11-0.01
0.740.70.420.720.50.81-0.11-0.80.530.660.260.740.880.730.730.880.730.750.290.520.290.720.640.810.34
0.520.50.410.670.180.50.09-0.70.230.480.250.520.530.560.420.640.580.520.10.520.330.430.470.560.1
0.50.610.350.610.090.490.3-0.470.090.310.020.490.130.610.540.440.610.530.330.290.330.570.480.050.1
0.830.970.710.910.260.940.33-0.810.280.640.10.830.420.960.890.790.960.850.240.720.430.570.810.390.28
0.960.830.560.910.670.85-0.1-0.540.610.910.570.950.460.890.950.860.90.950.330.640.470.480.810.290.57
0.430.370.230.430.320.52-0.13-0.710.350.420.160.430.860.390.330.70.40.420.110.810.560.050.390.290.15
0.640.290.210.330.860.25-0.640.070.790.720.830.650.380.40.50.510.390.62-0.010.340.10.10.280.570.15
Click cells to compare fundamentals

Ionis Pharmaceuticals Account Relationship Matchups

Ionis Pharmaceuticals fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets3.2B2.4B2.6B2.5B3.0B3.1B
Short Long Term Debt Total710M749M1.2B1.3B1.5B1.5B
Other Current Liab136.9M(128.4M)127.6M195.5M217.8M228.7M
Total Current Liabilities273M290M241M312M448.1M470.5M
Total Stockholder Equity1.5B843M772M573M386.7M265.7M
Property Plant And Equipment Net154M181M178M256M242.9M255.1M
Net Debt(1.8B)(1.1B)(954M)(642M)1.1B1.1B
Retained Earnings(707.5M)(1.2B)(1.2B)(1.4B)(1.8B)(1.7B)
Cash2.5B1.9B2.1B2.0B399.3M534.5M
Non Current Assets Total512M260M267M331M348.2M365.6M
Non Currrent Assets Other358M51.1M60.0M34.6M62.3M34.5M
Cash And Short Term Investments2.5B1.9B2.1B2.0B2.3B2.4B
Common Stock Shares Outstanding142.9M139.6M141.0M141.8M143.2M83.9M
Liabilities And Stockholders Equity3.2B2.4B2.6B2.5B3.0B3.1B
Non Current Liabilities Total1.3B1.3B1.6B1.6B2.2B2.3B
Other Current Assets158M162M168M190M184.4M193.7M
Other Stockholder Equity2.2B2.1B2.0B2.1B2.2B2.3B
Total Liab1.5B1.5B1.8B2.0B2.6B2.7B
Total Current Assets2.7B2.1B2.3B2.2B2.6B2.8B
Short Term Debt2.0M293.2M3.5M7.5M53.2M55.8M
Intangible Assets24.0M25.7M27.9M29.0M33.4M24.2M
Accounts Payable16.1M17.2M11.9M17.9M26.0M27.3M
Net Receivables63M76M62M26M97.8M102.7M
Property Plant And Equipment Gross153.7M181.1M280.7M256M339.7M356.7M
Accumulated Other Comprehensive Income(25.3M)(21.1M)(32.7M)(57.5M)(32.6M)(31.0M)
Short Term Investments1.8B1.5B1.2B1.7B1.9B2.0B
Other Assets310.6M78.0M319M35.0M40.2M57.3M
Long Term Debt770.0M515.7M1.2B1.2B1.2B1.3B
Property Plant Equipment153.7M181.1M178.1M74.3M85.4M79.6M
Other Liab490.1M424M352M287.8M330.9M170.0M
Current Deferred Revenue118M108M98M91M151.1M158.7M
Inventory18.2M22.0M24.8M22.0M28.4M29.8M
Net Tangible Assets1.4B815.4M742.7M572.9M658.8M531.9M
Retained Earnings Total Equity(707.5M)(1.2B)(1.2B)(1.4B)(1.3B)(1.4B)
Long Term Debt Total770.0M515.7M1.2B1.2B1.4B1.4B
Capital Surpluse2.2B2.1B2.0B2.1B2.4B1.7B

Pair Trading with Ionis Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Ionis Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Ionis Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Moving together with Ionis Stock

  0.76VRDN Viridian TherapeuticsPairCorr
  0.7EFTR Effector TherapeuticsPairCorr

Moving against Ionis Stock

  0.73DSGN Design TherapeuticsPairCorr
  0.68ELYM Eliem TherapeuticsPairCorr
  0.55ELVN Enliven TherapeuticsPairCorr
The ability to find closely correlated positions to Ionis Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Ionis Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Ionis Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Ionis Pharmaceuticals to buy it.
The correlation of Ionis Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Ionis Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Ionis Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Ionis Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Ionis Pharmaceuticals is a strong investment it is important to analyze Ionis Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Ionis Pharmaceuticals' future performance. For an informed investment choice regarding Ionis Stock, refer to the following important reports:
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Ionis Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors.
For more information on how to buy Ionis Stock please use our How to Invest in Ionis Pharmaceuticals guide.
You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.

Complementary Tools for Ionis Stock analysis

When running Ionis Pharmaceuticals' price analysis, check to measure Ionis Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ionis Pharmaceuticals is operating at the current time. Most of Ionis Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Ionis Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ionis Pharmaceuticals' price. Additionally, you may evaluate how the addition of Ionis Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Share Portfolio
Track or share privately all of your investments from the convenience of any device
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Fundamental Analysis
View fundamental data based on most recent published financial statements
Is Ionis Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ionis Pharmaceuticals. If investors know Ionis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ionis Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.44)
Earnings Share
(2.67)
Revenue Per Share
5.397
Quarterly Revenue Growth
(0.08)
Return On Assets
(0.08)
The market value of Ionis Pharmaceuticals is measured differently than its book value, which is the value of Ionis that is recorded on the company's balance sheet. Investors also form their own opinion of Ionis Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Ionis Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ionis Pharmaceuticals' market value can be influenced by many factors that don't directly affect Ionis Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ionis Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Ionis Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ionis Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.